GlaxoSmithKline
This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.
Inclusion Criteria: * Age greater than equal to (\>=)18 years OR of legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the Informed Consent Form. * Confirmed diagnosis of clinical VEXAS defined by: 1. Documented evidence of a canonical, pathogenic Ubiquitin-like modifier activating enzyme 1 (UBA1) mutation 2. Inflammatory manifestations: current or documented past involvement within 6 months of at least one organ system * Receiving glucocorticoid (GC) treatment (prednisone/prednisolone) for \>=4 consecutive weeks for \>=10 days prior to ra…
Momelotinib will be administered
Glucocorticoids (prednisone or prednisolone) will be administered
Placebo will be administered
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.